{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:32Z","timestamp":1787019572012,"version":"build-2736575974"},"reference-count":45,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Racial and ethnic representativeness in clinical trials is crucial to mitigate disparities in outcomes; however, diversity among hemophilia trials is unknown. The aim of this study is to examine the reporting and representation of race and ethnicity in trials of people with hemophilia (PwH). In this cross-sectional study, the ClinicalTrials.gov database was queried in April 2023 for interventional clinical trials involving PwH between 2007 and 2022. The distribution of participants (observed) was compared with expected proportions based on US Hemophilia Treatment Center (HTC) and country-specific census data with observed-to-expected ratios (OERs). Of 129 trials included, 94.6% were industry sponsored, with a mean of 62 participants and mean age of 26.8 years. Overall, 52.0% (n\u00a0= 66) of trials reported data on race and ethnicity, increasing from 13.9% in 2007-2012 to 22.5% in 2013-2016 to 100% in 2017-2022 (P\u00a0= .001). Among these 66 trials, 65.8%, 22.8%, 5.1%, 3.9% of participants were White, Asian, Hispanic, and Black, respectively. OERs were 10% to 20% lower for White participants vs US HTC, and US, UK, and Canadian census populations and \u223c75% lower for Black or Hispanic participants when compared with US HTC and US census population. OERs for Asian participants were 1.6 to 3 times higher than Canada, US, and UK census populations. The reporting of race and ethnicity in hemophilia trials has drastically improved; however, Black and Hispanic PwH remain especially underrepresented. To address these disparities, stakeholders across the clinical trial enterprise need to implement strategies to ensure equitable participation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012862","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T16:05:29Z","timestamp":1711641929000},"page":"2351-2360","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Race and ethnicity reporting and representation in hemophilia clinical trials"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3624-6382","authenticated-orcid":false,"given":"Stacey A.","family":"Fedewa","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"},{"name":"2Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-6418","authenticated-orcid":false,"given":"Leonard A.","family":"Valentino","sequence":"additional","affiliation":[{"name":"3Rush University Hemophilia and Thrombophilia Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andee","family":"Koo","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Cafuir","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"},{"name":"2Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-4452","authenticated-orcid":false,"given":"Duc Q.","family":"Tran","sequence":"additional","affiliation":[{"name":"4Hemophilia of Georgia, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Antun","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"},{"name":"2Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2391-2016","authenticated-orcid":false,"given":"Christine L.","family":"Kempton","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"},{"name":"2Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2024052418405303900_bib1","volume-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","year":"2022"},{"key":"2024052418405303900_bib2","volume-title":"Enhancing the Diversity of Clinical Trial Populations\u2013Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry","year":"2020"},{"key":"2024052418405303900_bib3","first-page":"100252","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"Turner","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"21","key":"2024052418405303900_bib4","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1182\/bloodadvances.2021005148","article-title":"Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials","volume":"5","author":"Hantel","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2024052418405303900_bib5","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00125-022-05736-z","article-title":"Exploring ethnic representativeness in diabetes clinical trial enrolment from 2000 to 2020: a chronological survey","volume":"65","author":"Li","year":"2022","journal-title":"Diabetologia"},{"issue":"10","key":"2024052418405303900_bib6","doi-asserted-by":"crossref","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"17","key":"2024052418405303900_bib7","doi-asserted-by":"crossref","first-page":"e021108","DOI":"10.1161\/JAHA.121.021108","article-title":"Recruitment of Black adults into cardiovascular disease trials","volume":"10","author":"Prasanna","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"2024052418405303900_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajh.26018","article-title":"2021 clinical trials update: innovations in hemophilia therapy","volume":"96","author":"Croteau","year":"2021","journal-title":"Am J Hematol"},{"issue":"17","key":"2024052418405303900_bib9","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1001\/jama.2012.3424","article-title":"Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010","volume":"307","author":"Califf","year":"2012","journal-title":"JAMA"},{"key":"2024052418405303900_bib10","author":"ClinicalTrials.gov","year":"2023"},{"issue":"10221","key":"2024052418405303900_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"key":"2024052418405303900_bib12","author":"US Office of Information and Regulatory Affairs, Office of Management and Budget, Executive Office of the President","year":"1997"},{"key":"2024052418405303900_bib13","author":"Fernandez","year":"2020"},{"key":"2024052418405303900_bib14","volume-title":"Community Counts HTC Patient Profile","year":"2022"},{"key":"2024052418405303900_bib15","year":"2023"},{"issue":"4","key":"2024052418405303900_bib16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14012","article-title":"The World Federation of Hemophilia Annual Global Survey 1999-2018","volume":"26","author":"Stonebraker","year":"2020","journal-title":"Haemophilia"},{"key":"2024052418405303900_bib17","doi-asserted-by":"crossref","first-page":"106237","DOI":"10.1016\/j.cct.2020.106237","article-title":"Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications","volume":"101","author":"Fain","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"2024052418405303900_bib18","doi-asserted-by":"crossref","first-page":"e2022058552","DOI":"10.1542\/peds.2022-058552","article-title":"Race and ethnicity reporting and representation in pediatric clinical trials","volume":"151","author":"Brewster","year":"2023","journal-title":"Pediatrics"},{"issue":"10","key":"2024052418405303900_bib19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jamaoncol.2021.2137","article-title":"Promoting inclusion of members of racial and ethnic minority groups in cancer drug development","volume":"7","author":"Fashoyin-Aje","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024052418405303900_bib20","doi-asserted-by":"crossref","first-page":"107184","DOI":"10.1016\/j.cct.2023.107184","article-title":"A\u00a0framework for setting enrollment goals to ensure participant diversity in sponsored clinical trials in the United States","volume":"129","author":"Cullen","year":"2023","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"2024052418405303900_bib21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/hae.13734","article-title":"Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources","volume":"25","author":"Okolo","year":"2019","journal-title":"Haemophilia"},{"issue":"3","key":"2024052418405303900_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13998","article-title":"Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres","volume":"26","author":"Soucie","year":"2020","journal-title":"Haemophilia"},{"key":"2024052418405303900_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"2024052418405303900_bib24","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1200\/JOP.19.00662","article-title":"Barriers to participation in therapeutic clinical trials as perceived by community oncologists","volume":"16","author":"Wong","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"2024052418405303900_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"issue":"4","key":"2024052418405303900_bib26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","article-title":"Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators","volume":"59","author":"Soucie","year":"1998","journal-title":"Am J Hematol"},{"key":"2024052418405303900_bib27","unstructured":"European Haemophilia Network\n          . EUHAT. 2023. Accessed 18 January 2023. https:\/\/www.euhanet.org\/."},{"key":"2024052418405303900_bib28","unstructured":"ASH DEI toolkit for clinical trial sponsors\n          . American Society of Hematology. 2023. Accessed 18 January 2023. https:\/\/www.hematology.org\/-\/media\/hematology\/files\/dei\/ash-dei-toolkit-for-clinical-trial-sponsors.pdf."},{"issue":"suppl 1","key":"2024052418405303900_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2019GS121537","article-title":"Improving access to hemophilia care in sub-Saharan Africa by capacity building","volume":"3","author":"Diop","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024052418405303900_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/17474086.2023.2178410","article-title":"Lived experience experts: a name created by us for us","volume":"16","author":"Vazquez","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"2024052418405303900_bib31","doi-asserted-by":"crossref","first-page":"e2127792","DOI":"10.1001\/jamanetworkopen.2021.27792","article-title":"Demographic and health behavior factors associated with clinical trial invitation and participation in the United States","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2024052418405303900_bib32","doi-asserted-by":"crossref","first-page":"e2021052595","DOI":"10.1542\/peds.2021-052595","article-title":"Disparities by ethnicity in enrollment of a clinical trial","volume":"149","author":"Coon","year":"2022","journal-title":"Pediatrics"},{"issue":"6","key":"2024052418405303900_bib33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/1740774512458992","article-title":"Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment","volume":"9","author":"Penberthy","year":"2012","journal-title":"Clin Trials"},{"issue":"3","key":"2024052418405303900_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/djaa155","article-title":"\"When Offered to Participate\": a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","volume":"113","author":"Unger","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"16","key":"2024052418405303900_bib35","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2007.14.8114","article-title":"Influence of clinical communication on patients' decision making on participation in clinical trials","volume":"26","author":"Albrecht","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024052418405303900_bib36","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.2105\/AJPH.2013.301706","article-title":"A\u00a0systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders","volume":"104","author":"George","year":"2014","journal-title":"Am J Public Health"},{"issue":"5","key":"2024052418405303900_bib37","doi-asserted-by":"crossref","first-page":"e2111629","DOI":"10.1001\/jamanetworkopen.2021.11629","article-title":"Factors associated with racial\/ethnic group-based medical mistrust and perspectives on COVID-19 vaccine trial participation and vaccine uptake in the US","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2024052418405303900_bib38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"2024052418405303900_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/hae.13078","article-title":"Physician trust and depression influence adherence to factor replacement: a single-centre cross-sectional study","volume":"23","author":"Tran","year":"2017","journal-title":"Haemophilia"},{"issue":"3","key":"2024052418405303900_bib40","first-page":"324","article-title":"Improving African American women's engagement in clinical research: a systematic review of barriers to participation in clinical trials","volume":"114","author":"Le","year":"2022","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"2","key":"2024052418405303900_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cct.2013.03.007","article-title":"A\u00a0systematic review of the factors influencing African Americans' participation in cancer clinical trials","volume":"35","author":"Rivers","year":"2013","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"2024052418405303900_bib42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jcph.1978","article-title":"Racial and ethnic differences in drug disposition and response: review of new molecular entities approved between 2014 and 2019","volume":"62","author":"Ramamoorthy","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"2024052418405303900_bib43","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jtha.2023.01.013","article-title":"Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor","volume":"21","author":"Elsheikh","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2024052418405303900_bib44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024052418405303900_bib45","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ehjcvp\/pvac040","article-title":"Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events","volume":"8","author":"Tamargo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2351\/2226490\/blooda_adv-2024-012862-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2351\/2226490\/blooda_adv-2024-012862-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T14:41:17Z","timestamp":1716561677000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/10\/2351\/515532\/Race-and-ethnicity-reporting-and-representation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012862","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}